Abstract : A prospective case-control Study was conducted from September 2019 to August 2021 in the Department of General Surgery, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune. 81 patients were diagnosed as moderate to severe Acute Pancreatitis by CT Severity Index. They were randomly assigned to two groups. Standard institutional protocol was followed for treatment in Group-B, while Group-A was administered subcutaneous injection 100 mcg Octreotide eight hourly for five days. The Octreotide group did not experience any significant pain relief, decrease in TLC/serum amylase/ serum lipase/ CRP or duration of hospital stay. There was no significant difference among both the groups regarding occurrence of complications at 6 and 12 months. Octreotide did not prove to be an effective drug for management of acute pancreatitis and prevention of its complications.